ACCP and NBS catching the eye of analysts Print E-mail
By Staff and Wire Reports   
Wednesday, 28 July 2010 08:10

Zacks Investment Research has issued a research update summarizing some of the recent positive developments that Access Pharmaceuticals Inc. (OTC:ACCP.OB) has been able to achieve which have led to reiteration of the 'Outperform' rating on ACCP and a six-twelve month price target of $8.00.

Currently the stock trades at just under $2.  The full report on Access Pharmaceuticals can be downloaded here.

As we have reported in recent weeks, the Access' FDA approved product, MuGuard has big fnancial and medical potential and it has attracted the attention of several big players in the onocology pharmaceuticals space. Recently we reported that the company intends to educate the oncology medicine community about the product going forward, but sources have told BioMedReports in the past that the company could decide to sell the technology to one of those bigger pharma players- whose deeper pockets and marketing resources could help launch the product faster and on a much bigger scale.

Read our exclusive interview with Jeffrey Davis, CEO of Access Pharmaceuticals here.

Sources are telling us that Neostem (AMEX:NBS) may be getting positive coverage by at least one analyst in the days ahead and that could turn into a nice trade for some of our readers.

Shares of the company have been rising steadily during the past few sessions after getting hammered and finding themselves oversold in recent weeks despite some very positive news flow. Shorts may finally be forced to cover if they haven't begun to do so already.

 

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter